Skip to main content

Smith & Nephew Plc Value Stock - Dividend - Research Selection

Smith + Nephew Plc

ISIN: GB0009223206, WKN: 502816

Market price date: 22.01.2021
Market price: 22,25 USD




Smith + Nephew Plc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 25-02-2020
Cash flow
Net operating cash flow 1.168.000.000
Capital Expenditures -408.000.000
Free cash flow 760.000.000
Balance sheet
Total Equity 5.141.000.000
Liabilities & Shareholders equity 9.299.000.000
Income statement
Net income 600.000.000
Eps (diluted) 0,700
Diluted shares outstanding 857.143.000
Net sales/revenue 5.138.000.000

Fundamental ratios calculated on: 22-01-2021

Ratios
Key figures 22-01-2021
Cash flow
P/C 16,33
   
P/FC 25,09
Balance sheet
ROI6,45
ROE55,29
Income statement
P/E31,79
Div. Yield0,00%
P/B3,71
P/S3,71


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolSNNUF
Market Capitalization19.071.432.704,00 USD
CountryUnited Kingdom
IndicesFTSE 100
SectorsHealth service
Raw Data SourceIFRS in Millionen USD
Stock Split
Internetwww.smith-nephew.com


Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.smith-nephew.com